Literature DB >> 23660576

The burden of HIV: insights from the Global Burden of Disease Study 2010.

Katrina F Ortblad1, Rafael Lozano, Christopher J L Murray.   

Abstract

OBJECTIVES: To evaluate the global and country-level burden of HIV/AIDS relative to 291 other causes of disease burden from 1980 to 2010 using the Global Burden of Disease Study 2010 (GBD 2010) as the vehicle for exploration.
METHODS: HIV/AIDS burden estimates were derived elsewhere as a part of GBD 2010, a comprehensive assessment of the magnitude of 291 diseases and injuries from 1990 to 2010 for 187 countries. In GBD 2010, disability-adjusted life years (DALYs) are used as the measurement of disease burden. DALY estimates for HIV/AIDS come from UNAIDS' 2012 prevalence and mortality estimates, GBD 2010 disability weights and mortality estimates derived from quality vital registration data.
RESULTS: Despite recent declines in global HIV/AIDS mortality, HIV/AIDS was still the fifth leading cause of global DALYs in 2010. The distribution of HIV/AIDS burden is not equal across demographics and regions. In 2010, HIV/AIDS was ranked as the leading DALY cause for ages 30-44 years in both sexes and for 21 countries that fall into four distinctive blocks: Eastern and Southern Africa, Central Africa, the Caribbean and Thailand. Although a majority of the DALYs caused by HIV/AIDS are in high-burden countries, 20% of the global HIV/AIDS burden in 2010 was in countries where HIV/AIDS did not make the top 10 leading causes of burden.
CONCLUSION: In the midst of a global economic recession, tracking the magnitude of the HIV/AIDS epidemic and its importance relative to other diseases and injuries is critical to effectively allocating limited resources and maintaining funding for effective HIV/AIDS interventions and treatments.

Entities:  

Mesh:

Year:  2013        PMID: 23660576      PMCID: PMC3748855          DOI: 10.1097/QAD.0b013e328362ba67

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


Introduction

In the last 30 years, the HIV/AIDS epidemic has emerged as one of the major challenges for the world, going from a relatively small problem in the 1980s to one of the leading causes of mortality and burden over the last decade [1-3]. The global trend is towards a larger and larger share of disease burden coming from noncommunicable diseases and injuries; however, HIV/AIDS is a dramatic exception [2-4]. Mortality and burden from HIV/AIDS increased steadily until around 2004, against the general trend of declining infectious disease burden. The HIV/AIDS epidemic has been truly global with 186 countries reporting HIV cases or deaths in 2012 [5,6]. Substantial concerted global action has emerged around the HIV/AIDS epidemic. New institutions have been formed: UNAIDS in 1996 [7] and the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) as well as the US President's Emergency Plan for AIDS Relief (PEPFAR) in 2002 [8,9]. These new global actors with substantial commitments to HIV/AIDS have been, along with many other nongovernmental programmes, key in raising national policy awareness in many affected countries and in scaling up access to antiretroviral therapies (ARTs) [10,11]. In 2011, eight million HIV-positive people received ARTs (a 20-fold increase since 2003), translating into 54% of all eligible people in low and middle-income countries [5]. Expansion of ART coverage is likely to have contributed to the reversal of the global trend in HIV/AIDS mortality. Successful scale-up of ARTs and the progress in reducing HIV/AIDS mortality have sparked excitement in the global community, and ambitious goals have followed [12]. In 2011, UNAIDS released its ‘Getting to Zero’ campaign with a vision that entails a future generation with ‘zero new HIV infections, zero discrimination and zero AIDS-related deaths’ [13,14]. Many factors have contributed to the achievements of the global response to the epidemic; new financial resources are likely to have been critical. Between 2002 and 2010, development assistance for health (DAH) targeted for HIV/AIDS increased from US$1.4 billion to US$6.8 billion (385.7%) [15]; and this does not include the substantial funds spent by low- and middle-income countries themselves [13]. Since 2010, however, levels of DAH have stagnated, as the long-run effects of the global financial crisis become apparent in the budgets of high-income countries. Because of the success of ART programmes and the continued evolution of the epidemic, the numbers of individuals who need ARTs will continue to rise steadily [5]. Increasing need for resources for HIV/AIDS programmes in the context of flat-line budgets is also happening in parallel with renewed attention to other health problems such as child mortality, maternal mortality and more recently noncommunicable diseases [15]. Maintaining and expanding the response to the HIV/AIDS epidemic will require continued emphasis on quantifying the magnitude of the impact of the epidemic in each country. UNAIDS and the WHO provide bi-annual assessments of the epidemic in terms of incidence of new infections, the prevalence of people living with HIV and deaths from HIV/AIDS for the vast majority of countries [5,16-18]. These analyses have been invaluable in garnering policy attention and response. The financial needs of HIV/AIDS programmes during a period of stagnant DAH levels highlight the importance of tracking the HIV/AIDS epidemic in the context of other health problems. At the national level, understanding the importance of the HIV/AIDS epidemic and its trends is facilitated by measuring the burden of disease in units that allow comparison with other major conditions. Comparable metrics of disease burden provide much-needed information on where the epidemic remains one of the dominant causes of health loss and where the burden is still rising despite progress in many countries [19]. The Global Burden of Disease Study 2010 (GBD 2010) [1-3,20-25] provides a comprehensive coherent view of the magnitude of 291 diseases and injuries from 1990 to 2010 for 187 countries. GBD 2010 uses a consistent set of definitions, approaches to data and methods to quantify health loss from all these diseases and injuries [21]. Multiple metrics are used to compare conditions, including death numbers, age-specific mortality rates, years of life lost due to premature mortality (YLLs), years lived with disability (YLDs) and disability-adjusted life years (DALYs). DALYs are a summation of YLLs and YLDs and serve as an overall metric of disease burden. In this study, we use GBD 2010 to understand the magnitude of the HIV/AIDS epidemic at the national level, in the context of all other major health problems, and how it has been changing over the last two decades.

Materials and methods

The data, efforts to improve the quality of the data and modelling strategies used in the GBD 2010 study are described in detail elsewhere [1-3,20-25]. For GBD 2010, mortality estimates were generated for 235 diseases and injuries, 187 countries, 20 age groups, both sexes and three decades (1980–2010), whereas DALY estimates were generated for 291 causes of burden, 21 regions, 20 age groups, both sexes and 3 years (1990, 2005 and 2010). In this study, we provide a synopsis of the HIV/AIDS-specific methods used in GBD 2010. To derive estimates of HIV/AIDS burden and mortality, we relied upon UNAIDS’ 2012 prevalence estimates, mortality estimates derived from quality vital registration sources as well as UNAIDS’ 2012 mortality estimates, and GBD 2010 disability weights (DWs). HIV/AIDS DALY estimates are presented here for the first time for 187 countries. We collaborated with UNAIDS to derive our cause-specific mortality estimates. This collaboration resulted in the use of a hybrid modelling method that selected mortality estimates from either the Cause of Death Ensemble model (CODEm) or UNAIDS 2012 revision estimates on a country-by-country basis [1]. CODEm, which was designed to develop ensembles of best-performing models, is the cause of death modelling approach that was used for a majority of the diseases and injuries in GBD 2010 (see Foreman et al.[26] for more detail.) For 33 countries with complete and high-quality vital registration systems, we used CODEm (Table 1). For the remaining countries, cause of death data are not sufficient for analysis because either there are few deaths recorded or there is a systematic misclassification of deaths in vital registration or verbal autopsy studies. For these countries, estimates of HIV/AIDS mortality with uncertainty by age and sex were provided directly by UNAIDS from their 2012 revisions in May 2011. For Thailand and Panama, the UNAIDS 2012 estimates we received were dramatically higher than UNAIDS’ 2010 estimates and were inconsistent with our all-cause mortality evidence; for these two countries, we used UNAIDS’ 2010 revision estimates. Uncertainty in cause of death model predictions has been captured using standard simulation methods by taking 1000 draws for each age, sex, country, year and cause [1,27].
Table 1

Countries with high-quality vital registration systems.

Antigua and BarbudaDominicaNorway
ArgentinaFrancePortugal
AustraliaGermanySaint Lucia
AustriaGrenadaSaint Vincent and the Grenadines
BarbadosIrelandSingapore
BelgiumItalySpain
CanadaJapanSweden
ChileLuxembourgSwitzerland
Costa RicaMaltaUnited Kingdom
CubaNetherlandsUnited States
DenmarkNew ZealandUruguay
A key part of the GBD 2010 cause of death estimation strategy is to enforce consistency between the sum of cause-specific mortality and independently assessed levels of all-cause mortality derived from demographic sources for every age-sex-country-year group (see Wang et al.[22] for details on the all-cause mortality analysis.) Uncertainty in every GBD 2010 cause of death model outcome had to be taken into account because some causes are known with much greater precision than others. To enforce consistency, we used a simple algorithm called CoDCorrect; at the level of each draw from the posterior distribution of each cause, we proportionately rescaled every cause such that the sum of the cause-specific estimates equaled the number of deaths from all causes (see Lozano et al.[1] for more details on CoDCorrect.) Estimates of HIV/AIDS mortality in a given country were proportionally adjusted less than other causes except where estimated HIV mortality in an age-sex group was greater than all-cause mortality, as there is less uncertainty surrounding the initial estimates (provided in large part by UNAIDS) than most other causes. To calculate DALYs attributable to HIV/AIDS, HIV/AIDS-specific YLLs and YLDs were computed and then summed together. YLLs are computed by multiplying the number of deaths at each age x by a standard life expectancy at age x[28], and YLDs are the product of prevalence times the DW for a particular disease sequelae [3]. DWs are scaled from 0 to 1 and represent the severity of health loss associated with that health state. A value of 0 implies that a health state is equivalent to full health, and a value of 1 implies that a state is equivalent to death (see Salomon et al.[23] for more detail). In GBD 2010, HIV/AIDS has five unique YLD sequelae, each with their own DW. The HIV/AIDS-specific disease sequelae are HIV disease resulting in mycobacterial infection (DW of 0.399), HIV pre-AIDS asymptomatic (DW of 0.051), HIV pre-AIDS symptomatic (DW of 0.221), AIDS with antiretrovirals (DW of 0.053) and AIDS without antiretrovirals (DW of 0.547) [23]. UNAIDS 2012 prevalence estimates were used to calculate HIV/AIDS-specific YLDs and these were disaggregated into the various HIV/AIDS sequelae using the fraction of tuberculosis (TB)-HIV reported in WHO TB case notifications, data on antiretroviral coverage from PEPFAR, GFATM and UNAIDS, and UNAIDS CD4 cell count data [29]. In GBD 2010, uncertainty in DALYs by cause reflects uncertainty in YLLs and YLDs [2]. Uncertainty for HIV/AIDS-specific YLLs encompasses uncertainty in the levels of all-cause mortality in each age-sex-country-year [22] as well as uncertainty in the HIV/AIDS mortality estimation for that age-sex-country-year [1], whereas uncertainty for HIV/AIDS-specific YLDs comes from the uncertainty surrounding the 2012 revision prevalence estimates provided directly by UNAIDS. Comorbidity is taken into account in the GBD 2010 by using all prevalence data and running a microsimulation for each country age and sex group [3]. Within each country for each time period, leading causes of DALYs have been computed and ranked. Ranks are calculated at the draw level and means are taken from these ranks. Mean ranks for all causes are compiled and sorted and then rank integer values are assigned.

Results

Figure 1 shows the evolution of global deaths from the HIV/AIDS epidemic from 1980 to 2010. Over this period, deaths increased dramatically until peaking in 2006; the annual rate of increase in global mortality from 1980 to 2006 was 19.4%. Since 2006, global HIV/AIDS mortality has steadily declined at an average annual rate of 4.17%. The decline in HIV/AIDS mortality reflects both declining incidence in some settings and the impact of the rapid scale-up of ART in some countries with large epidemics [30]. This figure does not put the magnitude of the HIV/AIDS epidemic in context. Figure 2 shows the leading causes of disease burden measured using DALYs in 1990 and 2010. HIV/AIDS was the 33rd most important cause of burden in 1990 and has increased dramatically to the fifth leading cause of disease burden in 2010. In absolute terms, the burden of HIV/AIDS increased during that period by 354%. To add further context, from 1990 to 2010, global YLDs from HIV/AIDS increased by 109.4%, compared with a 2.5% increase in YLDs from all causes [3], while global age-standardized mortality from HIV/AIDS increased by 258.4%, compared with a 21.5% decline in global age-standardized all-cause mortality during this same period [1,22]. In 2010, HIV accounted for 2.8% of global deaths and 3.3% of global DALYs. Despite the recent declines in global HIV/AIDS mortality, today, HIV/AIDS remains one of the leading global causes of both mortality and burden.
Fig. 1

Global HIV/AIDS mortality, 1980–2010.

Fig. 2

Global ranks for top 25 causes of disability-adjusted life years, 1990–2010.

Global HIV/AIDS mortality, 1980–2010. This illustration shows global HIV/AIDS mortality over time with 95% confidence intervals. Global ranks for top 25 causes of disability-adjusted life years, 1990–2010. Causes that are communicable, maternal, neonatal or nutritional deficiencies are shown in red, noncommunicable causes are in blue and injuries are in green. Number of global DALYs and the percentage of global DALYs attributable to each cause are included. Percentage change in DALYs from 1990 to 2010 by cause is also included on the right-hand side. HIV/AIDS and road injuries are the only top 10 causes of burden that are concentrated in young adults. Due to the nature of HIV/AIDS transmission and the timing of sexual contact, most of the burden of HIV/AIDS is in young adults. In fact, HIV/AIDS is the number one cause of burden for men in age groups 30–34, 35–39 and 40–44 years, and for women from ages 25–44 years (Fig. 3). In children under the age of 5 years, HIV/AIDS ranks as the 11th cause of burden for both men and women (Fig. 3). At older ages, HIV/AIDS is not a leading cause of disease burden. In countries of the world with large epidemics, such as in Eastern and Southern Africa, the concentration of HIV/AIDS in young adult age groups makes the disease an overwhelming health problem. For example, in South Africa in 2010, 75% of deaths in the 30–34 age group are from HIV/AIDS; in women, this percentage goes up to 84%. In the same age group, there are 78 countries where HIV/AIDS accounts for more than 10% of all deaths. As a majority of the HIV/AIDS burden is concentrated in these younger age groups, DALYs attributable to the disease are dominated by premature mortality; in 2010, YLLs contributed to 94.7% of global HIV/AIDS DALYs.
Fig. 3

Global HIV/AIDS disability-adjusted life year rank by age and sex, 2010.

Global HIV/AIDS disability-adjusted life year rank by age and sex, 2010. This figure illustrates where HIV/AIDS ranks among other leading causes of global burden by age and sex. Five-year age groups are represented in this graph. Blue squares indicate men and pink diamonds indicate women. Global HIV/AIDS statistics mask the extraordinary epidemic burden in selected countries. In 2010, HIV/AIDS was ranked as the leading cause of DALYs in 21 countries shown in red in Fig. 4 and the second leading cause of DALYs in an additional seven countries. The countries where HIV/AIDS ranks as number one fall into four distinctive blocks: the countries in Eastern and Southern sub-Saharan Africa spanning from Kenya and Uganda in the east to Namibia and South Africa in the south; a second smaller set of countries in central sub-Saharan Africa including Equatorial Guinea, Gabon and Congo, where HIV/AIDS epidemics are smaller, but still the leading cause of burden; the third block is made up of Thailand alone, where HIV/AIDS is the leading cause of burden in that country; and the final set of countries is in the Caribbean, including Bahamas, Jamaica and Suriname. Although HIV/AIDS may be a leading cause of DALYs in 21 countries, it is a much bigger problem for some countries than others. For example, in South Africa and Suriname, two countries where HIV/AIDS is the leading cause of DALYs, HIV/AIDS contributed to 39.94% of total DALYs in South Africa in 2010 and only 8.46% of total DALYs in Suriname. In 26 other countries, HIV/AIDS is among the top five causes of burden but not the leading cause. These include Colombia, Guyana, Myanmar, Russia, Ukraine and a number of countries in sub-Saharan Africa. In some countries, such as India, HIV/AIDS is not a top 10 cause of burden (it ranks 15th) but still represents a substantial percentage of the global HIV/AIDS burden (11.4%). Table 2 shows the number of DALYs due to HIV/AIDS for each country, the percentage of disease burden and mortality in each country attributable to the epidemic, the percentage of the global HIV/AIDS burden present in that country, the percentage decline from peak HIV/AIDS mortality to present and the rank of HIV/AIDS compared with other leading burden causes at the country level.
Fig. 4

HIV/AIDS disability-adjusted life year rank by country, 2010.

Table 2

HIV/AIDS disability-adjusted life years and other HIV/AIDS burden metrics by country for 2010 with 95% confidence intervals.

CountryaHIV/AIDS DALY number (in thousands)% of total DALYs attributable to HIV/AIDS% of deaths attributable to HIV/AIDS% of global HIV/AIDS deaths% change of deaths from peak to presentHIV/AIDS DALY rank
South Africa11 915.619 (11 213.482, 12 639.352)40.0% (37.7%, 42.1%)41.1% (38.6%, 43.5%)14.6% (13.7%, 15.6%)−32.9% (−34.7%, −30.6%)1
India9265.130 (7200.253, 11 080.598)1.8% (1.4%, 2.1%)1.8% (1.4%, 2.2%)11.4% (9.0%, 13.5%)−8.7% (−13.6%, −3.5%)15
Nigeria9011.595 (8169.121, 9962.661)7.4% (6.4%, 8.6%)9.2% (8.0%, 10.7%)11.1% (10.4%, 11.8%)−14.2% (−20.8%, −8.1%)2
Tanzania, United Republic of4674.416 (4277.838, 5073.069)17.3% (15.4%, 19.2%)21.2% (18.8%, 23.5%)5.7% (5.4%, 6.1%)−30.2% (−33.8%, −26.1%)1
Mozambique3853.077 (3292.985, 4500.451)19.5% (16.7%, 22.3%)21.7% (18.4%, 25.0%)4.7% (4.0%, 5.6%)−13.0% (−17.3%, −8.7%)1
Kenya3000.991 (2667.260, 3336.807)15.3% (13.5%, 17.1%)18.1% (15.8%, 20.5%)3.7% (3.4%, 4.0%)−53.5% (−57.6%, −49.4%)1
Uganda2868.064 (2520.930, 3238.720)14.7% (12.9%, 16.7%)17.2% (14.9%, 19.7%)3.5% (3.2%, 3.8%)−53.3% (−58.8%, −46.9%)1
Congo, the Democratic Republic of the2734.090 (2301.912, 3238.823)4.8% (4.0%, 5.8%)5.9% (4.9%, 7.2%)3.3% (3.0%, 3.7%)−2.7% (−4.4%, −1.0%)5
Malawi2631.089 (2371.300, 2905.022)21.0% (18.8%, 23.6%)23.6% (21.0%, 26.6%)3.2% (3.0%, 3.5%)−40.8% (−44.3%, −36.6%)1
Russian Federation2371.550 (1912.480, 2853.925)3.7% (3.0%, 4.5%)2.5% (1.9%, 3.0%)2.9% (2.3%, 3.5%)−0.5% (−5.3%, 4.0%)4
Zimbabwe2332.785 (2109.610, 2561.014)25.2% (23.2%, 27.6%)25.2% (22.7%, 27.8%)2.9% (2.6%, 3.1%)−47.5% (−51.5%, −43.2%)1
Zambia1831.769 (1592.574, 2077.554)18.3% (16.1%, 20.7%)20.0% (17.3%, 23.0%)2.2% (2.1%, 2.4%)−60.5% (−64.9%, −55.0%)1
China1751.701 (1258.816, 2330.904)0.6% (0.4%, 0.7%)0.4% (0.3%, 0.6%)2.2% (1.5%, 2.9%)0.0% (0.0%, 0.0%)38
Cameroon1548.028 (1309.968, 1814.597)11.7% (9.8%, 13.8%)13.6% (11.4%, 16.2%)1.9% (1.7%, 2.2%)−22.3% (−30.8%, −12.4%)2
Ethiopia1317.546 (1083.156, 1558.28)3.0% (2.4%, 3.6%)3.1% (2.5%, 3.8%)1.6% (1.4%, 1.8%)−67.6% (−72.3%, −62.9%)8
Côte d’Ivoire1200.274 (1012.450, 1389.329)8.1% (6.7%, 9.5%)9.5% (7.9%, 11.3%)1.5% (1.3%, 1.7%)−50.1% (−57.4%, −40.9%)4
Thailand1123.300 (959.228, 1332.434)5.6% (4.8%, 6.6%)4.4% (3.6%, 5.5%)1.4% (1.2%, 1.7%)−58.8% (−64.2%, −50.3%)1
Myanmar1098.668 (819.800, 1463.160)5.1% (4.2%, 6.2%)5.1% (4.1%, 6.3%)1.3% (1.0%, 1.8%)−10.9% (−23.4%, 2.3%)4
Ukraine1044.023 (840.529, 1292.452)5.1% (4.1%, 6.3%)3.3% (2.6%, 4.2%)1.3% (1.1%, 1.5%)−2.0% (−4.5%, 0.1%)3
Brazil993.330 (818.809, 1201.471)1.8% (1.5%, 2.2%)1.7% (1.3%, 2.2%)1.2% (1.0%, 1.5%)−45.3% (−58.1%, −31.2%)11
Sudan886.974 (621.793, 1169.102)4.7% (3.2%, 6.2%)6.4% (4.3%, 8.6%)1.1% (0.8%, 1.4%)−0.8% (−3.8%, 5.6%)4
Ghana886.554 (756.301, 1041.249)7.7% (6.5%, 9.1%)8.9% (7.5%, 10.6%)1.1% (1.0%, 1.2%)−31.0% (−39.9%, −20.3%)2
Lesotho680.410 (619.487, 746.453)32.8% (30.1%, 36.1%)33.0% (29.9%, 36.4%)0.8% (0.8%, 0.9%)−26.1% (−29.4%, −22.8%)1
Angola664.303 (413.188, 1020.523)5.8% (3.8%, 8.5%)7.0% (4.3%, 10.6%)0.8% (0.5%, 1.2%)−7.3% (−24.5%, 14.0%)4
Indonesia650.613 (392.311, 984.665)0.8% (0.5%, 1.3%)0.8% (0.4%, 1.2%)0.8% (0.5%, 1.2%)0.0% (0.0%, 0.0%)30
Viet Nam618.322 (473.224, 786.714)2.9% (2.2%, 3.7%)2.6% (1.9%, 3.4%)0.8% (0.6%, 1.0%)0.0% (0.0%, 0.0%)6
United States587.495 (514.663, 662.786)0.7% (0.6%, 0.8%)0.5% (0.4%, 0.5%)0.7% (0.6%, 0.8%)−75.6% (−78.9%, −71.6%)34
Burundi553.394 (387.069, 718.847)8.9% (6.7%, 10.3%)10.0% (7.6%, 11.7%)0.7% (0.5%, 0.9%)−45.5% (−67.2%, −28.5%)2
Central African Republic488.383 (407.268, 575.145)10.7% (9.1%, 12.3%)12.6% (10.5%, 14.8%)0.6% (0.5%, 0.7%)−5.9% (−19.9%, 15.1%)3
Chad482.579 (381.818, 602.494)4.5% (3.5%, 5.7%)5.5% (4.1%, 7.2%)0.6% (0.5%, 0.7%)−35.9% (−45.9%, −21.6%)5
Colombia479.460 (340.898, 657.335)4.0% (2.9%, 5.4%)4.3% (2.9%, 6.0%)0.6% (0.4%, 0.8%)−11.9% (−18.2%, −3.7%)4
Burkina Faso368.232 (298.202, 448.533)2.4% (1.9%, 3.0%)3.1% (2.4%, 3.9%)0.5% (0.4%, 0.6%)−69.0% (−73.9%, −56.1%)8
Swaziland361.430 (325.628, 399.896)37.0% (33.4%, 40.6%)37.5% (33.3%, 42.1%)0.4% (0.4%, 0.5%)−30.3% (−33.6%, −25.5%)1
Mali333.827 (247.092, 425.618)2.5% (1.8%, 3.4%)3.4% (2.3%, 4.6%)0.4% (0.3%, 0.5%)−44.5% (−61.8%, −22.4%)10
Togo290.545 (245.359, 347.383)7.6% (6.2%, 9.2%)8.9% (7.3%, 11.1%)0.4% (0.3%, 0.4%)−13.4% (−18.1%, −9.6%)3
Rwanda286.722 (213.082, 361.762)5.5% (4.0%, 7.0%)6.3% (4.5%, 8.1%)0.4% (0.3%, 0.4%)−83.1% (−87.9%, −75.4%)3
Venezuela277.018 (200.431, 362.801)3.6% (2.6%, 4.8%)3.4% (2.4%, 4.5%)0.3% (0.3%, 0.4%)−4.7% (−8.9%, −1.5%)5
Somalia265.788 (181.919, 392.148)3.7% (2.5%, 5.2%)4.6% (3.1%, 6.7%)0.3% (0.2%, 0.5%)0.0% (0.0%, 0.0%)5
Namibia260.588 (168.426, 356.167)23.4% (16.3%, 30.1%)23.1% (15.1%, 30.7%)0.3% (0.2%, 0.4%)−66.2% (−75.2%, −58.4%)1
Mexico253.760 (81.821, 485.491)1.0% (0.3%, 1.9%)0.8% (0.2%, 1.7%)0.3% (0.1%, 0.6%)−69.2% (−86.9%, −28.5%)30
Congo244.566 (210.586, 286.990)9.7% (8.1%, 11.6%)10.5% (8.6%, 12.8%)0.3% (0.3%, 0.3%)−44.0% (−52.7%, −32.6%)1
Malaysia235.735 (182.263, 321.939)3.6% (2.7%, 4.8%)3.7% (2.8%, 5.1%)0.3% (0.2%, 0.4%)−15.1% (−23.9%, −4.4%)5
Botswana232.001 (207.821, 253.798)30.4% (27.3%, 33.3%)35.4% (31.3%, 40.0%)0.3% (0.3%, 0.3%)−74.0% (−76.5%, −71.0%)1
Nepal217.744 (140.530, 355.663)2.1% (1.3%, 3.3%)2.6% (1.6%, 4.3%)0.3% (0.2%, 0.4%)−9.8% (−27.1%, 10.5%)14
Madagascar202.962 (153.435, 255.767)2.0% (1.5%, 2.6%)2.5% (1.8%, 3.3%)0.2% (0.2%, 0.3%)−5.5% (−23.5%, 12.2%)12
Guinea202.798 (150.422, 267.384)2.8% (2.0%, 3.7%)3.3% (2.4%, 4.5%)0.2% (0.2%, 0.3%)−40.2% (−55.8%, −17.7%)9
Pakistan202.141 (123.765, 413.193)0.3% (0.2%, 0.5%)0.3% (0.2%, 0.6%)0.2% (0.2%, 0.5%)0.0% (0.0%, 0.0%)62
Niger181.019 (162.976, 206.315)1.3% (1.1%, 1.5%)1.8% (1.5%, 2.2%)0.2% (0.2%, 0.2%)−23.9% (−26.7%, −18.8%)11
Benin150.467 (117.805, 182.469)3.0% (2.3%, 3.7%)3.6% (2.7%, 4.5%)0.2% (0.1%, 0.2%)−60.0% (−72.2%, −32.2%)10
Sierra Leone131.187 (109.251, 155.300)3.3% (2.7%, 4.0%)4.4% (3.6%, 5.5%)0.2% (0.1%, 0.2%)−5.1% (−9.2%, 0.1%)7
Peru130.901 (51.836, 254.507)1.8% (0.7%, 3.6%)1.9% (0.7%, 3.9%)0.2% (0.1%, 0.3%)−54.7% (−83.0%, −11.5%)17
Senegal121.913 (73.858, 185.206)2.1% (1.3%, 3.2%)2.8% (1.5%, 4.4%)0.1% (0.1%, 0.2%)−15.7% (−26.2%, −8.0%)10
Gabon117.338 (67.003, 173.600)13.2% (7.9%, 19.1%)13.2% (7.4%, 19.8%)0.1% (0.1%, 0.2%)−18.4% (−37.5%, 5.1%)1
Liberia116.743 (95.635, 143.626)3.6% (2.9%, 4.5%)4.8% (3.8%, 5.9%)0.1% (0.1%, 0.2%)−23.4% (−37.4%, −1.5%)6
Iran, Islamic Republic114.605 (99.072, 132.010)0.6% (0.5%, 0.7%)0.7% (0.6%, 0.8%)0.1% (0.1%, 0.2%)−11.9% (−22.6%, 5.1%)33
Haiti113.863 (77.312, 172.118)0.8% (0.4%, 1.4%)0.7% (0.3%, 1.3%)0.1% (0.1%, 0.2%)−80.4% (−86.5%, −63.5%)13
Dominican Republic99.618 (74.507, 131.373)3.5% (2.6%, 4.6%)3.1% (2.2%, 4.2%)0.1% (0.1%, 0.2%)−58.6% (−68.5%, −45.2%)6
Guatemala93.800 (37.936, 180.740)2.0% (0.8%, 3.9%)2.1% (0.7%, 4.3%)0.1% (0.0%, 0.2%)0.0% (0.0%, 0.0%)13
Eritrea92.498 (33.058, 200.795)3.2% (1.2%, 6.6%)3.8% (1.2%, 8.2%)0.1% (0.0%, 0.2%)−44.4% (−70.1%, −16.5%)9
Argentina90.351 (79.079, 102.903)0.8% (0.7%, 1.0%)0.6% (0.5%, 0.7%)0.1% (0.1%, 0.1%)−22.0% (−34.1%, −7.8%)32
Papua New Guinea88.386 (56.119, 134.602)2.5% (1.7%, 3.4%)2.3% (1.5%, 3.2%)0.1% (0.1%, 0.2%)−51.2% (−66.3%, −34.5%)6
Ecuador82.083 (40.351, 137.704)2.3% (1.1%, 3.8%)2.6% (1.2%, 4.5%)0.1% (0.1%, 0.2%)−21.5% (−46.5%, 16.6%)12
Cambodia82.054 (47.590, 172.970)1.6% (0.9%, 3.4%)1.5% (0.8%, 3.5%)0.1% (0.1%, 0.2%)−86.2% (−89.4%, −68.8%)16
Uzbekistan78.136 (50.829, 111.878)0.8% (0.6%, 1.2%)1.0% (0.6%, 1.4%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)27
Morocco77.079 (48.165, 131.838)0.8% (0.5%, 1.4%)0.9% (0.5%, 1.5%)0.1% (0.1%, 0.2%)−8.7% (−39.9%, 36.3%)36
Honduras70.454 (36.224, 115.581)3.3% (1.7%, 5.3%)3.6% (1.7%, 6.0%)0.1% (0.0%, 0.1%)−37.9% (−59.4%, −1.3%)7
Equatorial Guinea65.337 (36.331, 98.197)12.1% (7.3%, 17.7%)14.4% (8.3%, 21.5%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)1
Bolivia60.820 (37.022, 89.851)1.8% (1.1%, 2.7%)2.3% (1.3%, 3.5%)0.1% (0.0%, 0.1%)−7.6% (−41.5%, 25.5%)14
Jamaica57.496 (37.513, 81.274)7.4% (5.0%, 10.2%)6.5% (4.2%, 9.3%)0.1% (0.0%, 0.1%)−49.5% (−62.2%, −32.0%)1
Spain56.243 (47.878, 65.193)0.5% (0.4%, 0.6%)0.3% (0.2%, 0.3%)0.1% (0.1%, 0.1%)−84.8% (−87.5%, −81.4%)44
Italy55.269 (47.017, 64.301)0.3% (0.3%, 0.4%)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.1%)−79.8% (−83.4%, −75.0%)56
Djibouti53.316 (33.465, 83.773)12.0% (8.2%, 17.3%)13.9% (9.0%, 20.5%)0.1% (0.0%, 0.1%)−18.0% (−46.6%, 23.7%)1
Mauritania52.505 (29.850, 83.348)3.0% (1.8%, 4.8%)3.9% (2.1%, 6.5%)0.1% (0.0%, 0.1%)−3.1% (−36.0%, 36.2%)10
France48.908 (41.904, 56.833)0.3% (0.3%, 0.3%)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.1%)−82.1% (−85.2%, −78.0%)61
Algeria48.627 (33.899, 65.595)0.6% (0.4%, 0.8%)0.7% (0.4%, 0.9%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)39
Gambia46.859 (14.259, 113.562)4.6% (1.5%, 10.7%)6.2% (1.7%, 14.4%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)6
Panama43.934 (22.383, 75.113)5.2% (2.8%, 8.6%)5.1% (2.5%, 8.6%)0.1% (0.0%, 0.1%)−51.8% (−76.4%, −13.3%)2
Portugal42.759 (36.893, 48.911)1.4% (1.2%, 1.7%)0.8% (0.7%, 0.9%)0.1% (0.0%, 0.1%)−28.9% (−40.6%, −14.7%)24
Guinea-Bissau40.327 (25.223, 61.72)3.3% (2.1%, 4.9%)3.8% (2.3%, 6.0%)0.0% (0.0%, 0.1%)−31.0% (−45.1%, −14.5%)8
Kyrgyzstan38.870 (21.261, 64.297)1.9% (1.1%, 3.1%)2.0% (1.1%, 3.4%)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.0%)15
Kazakhstan33.761 (28.206, 40.881)0.5% (0.4%, 0.6%)0.5% (0.4%, 0.6%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)40
Canada32.963 (27.214, 39.927)0.4% (0.3%, 0.5%)0.2% (0.2%, 0.3%)0.0% (0.0%, 0.0%)−66.6% (−73.5%, −57.0%)49
Romania32.850 (21.857, 45.866)0.4% (0.3%, 0.6%)0.3% (0.2%, 0.4%)0.0% (0.0%, 0.1%)−11.0% (−19.8%, 0.2%)46
Tunisia32.140 (18.314, 47.484)1.3% (0.8%, 1.9%)1.3% (0.8%, 1.9%)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.0%)21
Chile31.278 (26.109, 37.860)0.8% (0.7%, 1.0%)0.6% (0.5%, 0.7%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)33
Moldova30.638 (25.165, 36.928)2.1% (1.7%, 2.6%)1.5% (1.2%, 1.9%)0.0% (0.0%, 0.0%)−5.0% (−13.9%, 0.8%)10
El Salvador30.222 (9.145, 72.508)1.8% (0.5%, 4.1%)1.5% (0.4%, 3.8%)0.0% (0.0%, 0.1%)−49.9% (−88.7%, 56.3%)20
Trinidad and Tobago29.330 (26.319, 32.550)6.4% (5.6%, 7.3%)5.9% (5.1%, 6.7%)0.0% (0.0%, 0.0%)−22.6% (−30.7%, −11.7%)3
Germany29.224 (25.458, 33.116)0.1% (0.1%, 0.1%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−75.3% (−79.8%, −70.9%)94
Tajikistan28.214 (16.961, 39.411)1.2% (0.7%, 1.6%)1.5% (0.8%, 2.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)22
Greece26.674 (22.202, 31.726)0.8% (0.7%, 1.0%)0.5% (0.4%, 0.6%)0.0% (0.0%, 0.0%)−32.7% (−49.3%, −21.5%)25
Paraguay24.682 (7.259, 50.923)1.4% (0.4%, 2.9%)1.4% (0.3%, 3.0%)0.0% (0.0%, 0.1%)−29.6% (−69.4%, 17.4%)24
Afghanistan24.041 (12.641, 48.308)0.1% (0.1%, 0.2%)0.1% (0.1%, 0.3%)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.0%)77
Mauritius23.976 (19.610, 29.302)6.5% (5.4%, 8.0%)5.3% (4.0%, 7.1%)0.0% (0.0%, 0.0%)−5.7% (−13.1%, 1.9%)3
Turkmenistan22.889 (12.659, 33.554)1.5% (0.8%, 2.1%)1.6% (0.9%, 2.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)18
United Kingdom22.208 (18.939, 25.759)0.1% (0.1%, 0.2%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−63.5% (−69.0%, −56.5%)91
Korea, Republic of21.671 (16.485, 28.126)0.2% (0.2%, 0.3%)0.2% (0.1%, 0.2%)0.0% (0.0%, 0.0%)−11.7% (−14.5%, −8.4%)67
Cuba21.117 (10.586, 38.305)0.7% (0.3%, 1.2%)0.2% (0.2%, 0.2%)0.0% (0.0%, 0.0%)−0.6% (−20.5%, 22.9%)38
Egypt20.931 (12.958, 32.732)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)94
Guyana20.299 (6.869, 41.073)7.0% (2.5%, 13.2%)6.8% (2.2%, 13.5%)0.0% (0.0%, 0.0%)−60.6% (−82.2%, −35.8%)2
Philippines19.334 (12.917, 25.980)0.1% (0.0%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)114
Latvia18.655 (14.068, 24.059)2.2% (1.6%, 2.8%)1.4% (1.0%, 1.8%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)9
Serbia17.720 (11.487, 24.665)0.6% (0.4%, 0.8%)0.4% (0.2%, 0.5%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)37
Bahamas16.690 (15.571, 17.907)15.8% (14.3%, 17.3%)19.4% (17.5%, 21.2%)0.0% (0.0%, 0.0%)−35.7% (−40.2%, −31.3%)1
Suriname14.824 (13.025, 17.052)8.8% (7.7%, 10.1%)9.4% (8.0%, 11.2%)0.0% (0.0%, 0.0%)−27.3% (−42.3%, −8.4%)1
Lao People's Democratic Republic13.863 (5.010, 33.900)0.5% (0.2%, 1.3%)0.5% (0.1%, 1.4%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)45
Taiwan13.768 (10.918, 17.222)0.3% (0.2%, 0.3%)0.2% (0.1%, 0.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)67
Estonia13.431 (10.352, 16.861)3.0% (2.3%, 3.8%)1.8% (1.3%, 2.4%)0.0% (0.0%, 0.0%)−5.3% (−11.1%, −0.6%)5
Belarus12.747 (4.649, 25.540)0.3% (0.1%, 0.6%)0.2% (0.1%, 0.4%)0.0% (0.0%, 0.0%)−31.4% (−62.2%, 14.7%)59
United Arab Emirates12.129 (6.378, 19.932)0.9% (0.4%, 1.4%)1.8% (0.9%, 2.9%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)28
Poland12.076 (9.624, 14.953)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−62.5% (−73.5%, −46.6%)104
Bangladesh11.817 (7.759, 15.783)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)136
Bulgaria9.669 (7.033, 12.722)0.3% (0.2%, 0.4%)0.2% (0.1%, 0.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)50
Belize9.661 (8.139, 11.456)10.5% (8.8%, 12.7%)11.1% (8.9%, 13.7%)0.0% (0.0%, 0.0%)−11.3% (−33.1%, 58.8%)1
Sri Lanka9.506 (6.725, 12.831)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)76
Korea, Democratic People's Republic9.291 (7.207, 11.846)0.1% (0.1%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)93
Saudi Arabia9.142 (4.952, 14.679)0.2% (0.1%, 0.3%)0.2% (0.1%, 0.4%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)74
Costa Rica8.819 (7.551, 10.129)0.9% (0.8%, 1.1%)0.9% (0.7%, 1.0%)0.0% (0.0%, 0.0%)−24.9% (−38.3%, −10.5%)30
Lebanon8.524 (4.660, 13.686)0.9% (0.5%, 1.5%)0.8% (0.4%, 1.4%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)28
Uruguay8.369 (6.846, 10.28)0.9% (0.7%, 1.1%)0.5% (0.4%, 0.6%)0.0% (0.0%, 0.0%)−8.1% (−22.4%, 9.7%)32
Yemen8.210 (6.098, 10.875)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−9.1% (−36.3%, 29.9%)84
Australia8.156 (6.750, 9.769)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−77.9% (−82.4%, −72.5%)84
Hungary7.908 (5.944, 10.057)0.2% (0.2%, 0.3%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)−68.7% (−80.4%, −50.1%)68
Azerbaijan7.729 (5.195, 10.824)0.3% (0.2%, 0.4%)0.3% (0.2%, 0.4%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)55
Libyan Arab Jamahiriya7.215 (5.181, 9.861)0.5% (0.3%, 0.6%)0.5% (0.4%, 0.7%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)48
Turkey6.758 (3.793, 10.427)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−25.5% (−51.7%, 5.5%)132
Switzerland6.754 (5.848, 7.731)0.4% (0.3%, 0.4%)0.2% (0.2%, 0.2%)0.0% (0.0%, 0.0%)−81.6% (−84.8%, −77.4%)54
Japan6.731 (5.886, 7.597)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)−59.4% (−65.3%, −53.0%)135
Armenia6.543 (3.287, 13.771)0.7% (0.3%, 1.4%)0.5% (0.2%, 1.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)37
Cape Verde5.962 (2.834, 9.730)4.5% (2.3%, 7.1%)4.7% (2.1%, 7.4%)0.0% (0.0%, 0.0%)−34.6% (−62.8%, −5.7%)2
Georgia5.820 (3.602, 8.089)0.4% (0.2%, 0.5%)0.2% (0.1%, 0.3%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)50
Belgium5.266 (4.483, 6.120)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−59.9% (−66.5%, −50.5%)76
Netherlands5.205 (4.468, 5.965)0.1% (0.1%, 0.1%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−83.8% (−86.5%, −80.6%)94
Nicaragua4.338 (1.067, 19.944)0.3% (0.1%, 1.4%)0.3% (0.0%, 1.5%)0.0% (0.0%, 0.0%)−64.8% (−83.1%, 19.8%)76
Syrian Arab Republic4.022 (2.287, 6.320)0.1% (0.1%, 0.2%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)97
Austria3.844 (3.261, 4.489)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−70.7% (−76.0%, −64.8%)78
Bahrain3.566 (1.877, 5.868)1.4% (0.7%, 2.2%)2.4% (1.2%, 3.8%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)18
Lithuania3.538 (2.500, 4.790)0.3% (0.2%, 0.4%)0.2% (0.1%, 0.3%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)60
Israel3.246 (2.561, 4.183)0.2% (0.2%, 0.3%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)−60.3% (−71.4%, −44.1%)72
Singapore3.081 (2.653, 3.576)0.4% (0.4%, 0.5%)0.4% (0.3%, 0.5%)0.0% (0.0%, 0.0%)−45.9% (−53.8%, −35.6%)45
Denmark2.849 (2.422, 3.282)0.2% (0.2%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−77.3% (−81.7%, −71.9%)78
Kuwait2.746 (1.494, 4.326)0.5% (0.3%, 0.8%)0.8% (0.4%, 1.3%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)42
Sao Tome and Principe2.539 (1.645, 3.733)4.4% (2.9%, 6.3%)5.8% (3.5%, 8.6%)0.0% (0.0%, 0.0%)−22.3% (−47.6%, 15.2%)5
Macedonia, the Former Yugoslav Republic of2.405 (1.973, 2.859)0.4% (0.3%, 0.5%)0.3% (0.2%, 0.3%)0.0% (0.0%, 0.0%)−37.9% (−54.7%, −25.4%)46
Bosnia and Herzegovina2.391 (2.011, 2.808)0.2% (0.2%, 0.3%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)−23.8% (−40.9%, 7.5%)71
Albania2.374 (1.946, 2.877)0.3% (0.2%, 0.3%)0.2% (0.2%, 0.3%)0.0% (0.0%, 0.0%)−30.2% (−49.0%, −15.6%)58
Barbados2.047 (1.700, 2.403)2.4% (2.0%, 2.8%)1.8% (1.5%, 2.1%)0.0% (0.0%, 0.0%)−58.5% (−67.0%, −48.5%)9
Sweden1.943 (1.657, 2.258)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)−77.7% (−81.5%, −73.4%)105
Bhutan1.765 (1.103, 2.630)0.7% (0.4%, 1.0%)0.7% (0.4%, 1.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)36
Ireland1.722 (1.455, 2.046)0.2% (0.1%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−75.8% (−80.2%, −69.7%)87
Jordan1.269 (.709, 2.040)0.1% (0.1%, 0.2%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)100
Saint Vincent and the Grenadines1.264 (1.104, 1.454)3.6% (3.1%, 4.2%)3.2% (2.7%, 3.7%)0.0% (0.0%, 0.0%)−42.0% (−51.3%, −30.3%)6
Norway1.232 (1.046, 1.427)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−72.2% (−77.7%, −66.2%)100
Finland1.224 (1.040, 1.439)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−50.8% (−62.0%, −34.4%)105
Fiji1.128 (0.746, 1.599)0.4% (0.2%, 0.5%)0.3% (0.2%, 0.5%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)61
Mongolia1.066 (0.665, 1.430)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)90
Oman0.992 (0.786, 1.498)0.2% (0.1%, 0.3%)0.2% (0.2%, 0.4%)0.0% (0.0%, 0.0%)−57.7% (−71.4%, −25.8%)74
Czech Republic0.982 (.837, 1.138)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)−43.4% (−55.2%, −26.7%)124
Croatia0.977 (0.762, 1.240)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)−14.7% (−18.8%, −10.1%)109
Qatar0.952 (0.490, 1.533)0.3% (0.2%, 0.5%)0.7% (0.4%, 1.2%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)55
Saint Lucia0.927 (0.794, 1.075)1.8% (1.5%, 2.1%)1.2% (1.0%, 1.4%)0.0% (0.0%, 0.0%)−20.5% (−33.9%, −3.9%)12
New Zealand0.910 (0.766, 1.095)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−85.4% (−88.6%, −81.3%)99
Cyprus0.588 (0.542, 0.634)0.3% (0.3%, 0.4%)0.2% (0.2%, 0.2%)0.0% (0.0%, 0.0%)−62.7% (−66.0%, −59.6%)58
Grenada0.564 (0.484, 0.652)1.7% (1.5%, 2.0%)1.1% (0.9%, 1.3%)0.0% (0.0%, 0.0%)−30.6% (−43.4%, −13.8%)13
Slovenia0.547 (0.415, 0.714)0.1% (0.1%, 0.1%)0.1% (0.0%, 0.1%)0.0% (0.0%, 0.0%)−6.3% (−12.4%, 0.8%)105
Iraq0.462 (0.257, 0.735)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)162
Seychelles0.448 (0.390, 0.525)1.9% (1.7%, 2.3%)1.8% (1.6%, 2.2%)0.0% (0.0%, 0.0%)−26.4% (−31.9%, −20.0%)13
Antigua and Barbuda0.398 (0.346, 0.461)1.7% (1.5%, 2.0%)1.2% (1.0%, 1.4%)0.0% (0.0%, 0.0%)−30.7% (−43.1%, −13.5%)14
Iceland0.385 (0.310, 0.475)0.6% (0.4%, 0.7%)0.4% (0.3%, 0.5%)0.0% (0.0%, 0.0%)−17.6% (−31.9%, 1.7%)39
Slovakia0.374 (0.281, 0.492)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)−5.2% (−12.1%, 3.8%)133
Dominica0.363 (0.313, 0.418)1.7% (1.4%, 2.0%)1.2% (1.0%, 1.4%)0.0% (0.0%, 0.0%)−65.8% (−72.3%, −57.7%)12
Luxembourg0.333 (0.293, 0.375)0.3% (0.2%, 0.3%)0.1% (0.1%, 0.2%)0.0% (0.0%, 0.0%)−65.8% (−71.2%, −59.7%)63
Brunei Darussalam0.216 (0.191, 0.244)0.3% (0.2%, 0.3%)0.3% (0.2%, 0.3%)0.0% (0.0%, 0.0%)−24.8% (−37.7%, 1.0%)67
Kiribati0.196 (0.142, 0.264)0.5% (0.3%, 0.6%)0.4% (0.3%, 0.5%)0.0% (0.0%, 0.0%)−50.5% (−61.0%, −38.1%)49
Malta0.143 (0.127, 0.160)0.1% (0.1%, 0.2%)0.1% (0.1%, 0.1%)0.0% (0.0%, 0.0%)−57.7% (−64.2%, −49.8%)86
Maldives0.102 (0.08, 0.128)0.2% (0.1%, 0.2%)0.2% (0.2%, 0.3%)0.0% (0.0%, 0.0%)−52.2% (−64.2%, −36.6%)85
Montenegro0.094 (0.074, 0.119)0.0% (0.0%, 0.1%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)−12.0% (−16.0%, −7.9%)120
Occupied Palestinian Territory0.076 (0.043, 0.119)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)156
Comoros0.014 (0.006, 0.042)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)159
Timor-Leste0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)171
Micronesia, Federated States of0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)168
Solomon Islands0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)168
Tonga0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)166
Marshall Islands0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)172
Samoa0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)173
Andorra0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)164
Vanuatu0.000 (0.000, 0.000)0.0% (0.0%, 0.0%)0.0% (0.0%, 0.0%)0.0% (0.0%-0.0%)171

aCountries ordered by number of HIV/AIDS DALYs.

HIV/AIDS disability-adjusted life year rank by country, 2010. Colours correspond to bins of HIV/AIDS disease burden rank. Red indicates countries where HIV/AIDS is the leading cause of burden. Although HIV/AIDS is a global epidemic, a majority of the disease burden is concentrated in a handful of countries with particularly large epidemics. When evaluating the percentage of global HIV/AIDS DALYs by rank in 2010, the summation of HIV/AIDS DALYs for countries where HIV/AIDS is the leading cause or in the top five leading causes of burden accounts for 44.6 and 75.2% of global HIV/AIDS DALYs, respectively (Fig. 5). Sub-Saharan African countries, in particular, dominate the proportion of global HIV/AIDS DALYs; in 2010, the 47 countries in this region contributed to 70.9% of global DALYs attributable to HIV/AIDS. Compared with the peak in global HIV/AIDS burden around 2005, the fraction of global burden attributable to HIV/AIDS in countries where HIV/AIDS ranks as a leading cause has decreased. In 2005, 80.3% of the global epidemic burden compared with 75.2% in 2010 was in countries where HIV/AIDS ranked in the top five leading causes of disease burden. These percentages illustrate the recent shift in the burden of HIV/AIDS at the country level. Burden attributable to HIV/AIDS is decreasing in high-burden countries and shifting to affect a greater number of countries that have not historically had large epidemics and are struggling with other leading causes of burden. In 2010, for example, 20.0% of the HIV/AIDS burden was in countries where HIV/AIDS ranked higher than 10 compared with only 15.5% in 2005 (Fig. 5). Furthermore, although global HIV/AIDS mortality has been steadily decreasing since 2006, it has actually been on the rise for 98 countries during this same period (Table 2).
Fig. 5

Summation of country-level HIV/AIDS disability-adjusted life years by rank, 2010.

Summation of country-level HIV/AIDS disability-adjusted life years by rank, 2010. This figure illustrates the summation of HIV/AIDS DALYs for countries with similar HIV/AIDS DALY ranks in 2010. HIV/AIDS DALY ranks are listed along the bottom. The percentages on top of each bar indicate the proportion of global HIV/AIDS DALYs attributable to the summation of DALYs from all countries with that rank. The rank of HIV/AIDS among the leading causes of DALYs has generally increased over time to reflect the epidemic's progression; however, the change in the rank of HIV/AIDS DALYs has been more pronounced in some regions than others. In 1990, HIV/AIDS ranked as the third leading cause of DALYs in Southern sub-Saharan Africa, but did not even make the top 100 leading DALY causes in South Asia where it ranked 122nd (Fig. 6a, b). From 1990 to 2010, HIV/AIDS increased in the ranks of leading DALY causes for both of these regions and for other regions across the globe. The rate of increase in rank and relative HIV/AIDS burden impact, however, is again variable by region. In 2010, HIV/AIDS became the leading cause of DALYs in southern sub-Saharan Africa (having increased 1065% since 1990) but only ranked as the 17th leading burden cause in South Asia. Although the burden rank for HIV/AIDS may be lower in South Asia, the percentage change from 1990 to 2010 is nearly five-fold greater than the percentage change in southern sub-Saharan Africa during this period (4761% change for South Asia). The number of DALYs in southern sub-Saharan Africa compared with South Asia in 2010, however, is 1.63 times greater.
Fig. 6

Southern sub-Saharan Africa and South Asia ranks for top 25 causes of disability-adjusted life years, 1990–2010. (a) Southern sub-Saharan Africa; (b) South Asia.

Southern sub-Saharan Africa and South Asia ranks for top 25 causes of disability-adjusted life years, 1990–2010. (a) Southern sub-Saharan Africa; (b) South Asia. Causes that are communicable, maternal, neonatal or nutritional deficiencies are shown in red, noncommunicable causes are in blue and injuries are in green. Number of regional DALYs and the percentage of regional DALYs attributable to each cause are included. Percentage change in DALYs from 1990 to 2010 by cause is also included on the right-hand side.

Discussion

From 1990 to 2006, the burden of HIV/AIDS increased dramatically at the global level. Likely due to a combination of declines in incidence, massive scale-up of ART coverage [5,30,31] and rising coverage of PMTCT [32], the burden of HIV/AIDS has declined in the last half decade. Along with a few other interventions, such as bed nets for malaria [33-35], the scale-up of interventions for HIV/AIDS, particularly ART, stands as one of the extraordinary success stories for global health [5]. Clear and compelling links between donor funding for ART programmes and scale-up provide an excellent case for the impact of some DAH [36,37]. Because HIV/AIDS is concentrated in young adults and in selected countries, the burden, however, remains high even in some countries with marked ART scale-up. GBD 2010 provides a unique opportunity to see HIV/AIDS in context. Despite progress, the message is clear: HIV/AIDS is not gone. In 2010, the epidemic remains the number one cause of burden in 21 countries and the number two cause of burden in seven others. Further, HIV/AIDS mortality continued to increase from 2006 to 2010 in 98 countries. Although many of these countries have small epidemic burdens, greater attention and allocation of resources may need to be directed in these settings. A number of countries with large epidemics in Eastern and Southern Africa have seen substantial declines in HIV/AIDS mortality, such as Rwanda, Botswana and Zimbabwe (83.1, 74.0 and 47.5% decline in mortality from peak to present, respectively, Table 2). What this means is that, in 2005, 68.7% of global HIV/AIDS burden was in countries where HIV/AIDS is the leading or second leading cause of the burden of disease, and in 2010, this has been reduced to 59.4% (Fig. 5). It is likely easier to maintain policy focus and strong political engagement in the management of HIV/AIDS prevention and treatment programmes in settings where the disease is a truly dominant problem. Demographic and epidemiological trends, however, suggest that we should expect a larger share of the global burden of HIV/AIDS to occur in countries where HIV/AIDS is not a dominant or necessarily leading health problem. For example, HIV/AIDS may contribute to a relatively small fraction of a country's total disease burden but a large fraction of the global HIV/AIDS burden. In 2010, India's HIV/AIDS DALYs accounted for 11.4% of global HIV/AIDS DALYs and only 1.8% of the country's total burden (Table 2). By comparison, diarrhoeal diseases and ischemic heart diseases accounted for 5.2 and 5.1% of India's total DALYs, respectively, in 2010, making it challenging to sustain sufficient priority for HIV/AIDS programmes [38]. The global HIV/AIDS community will need to garner attention on the epidemic increasingly in settings where it is not a nation's dominant health problem. Several studies have shown the future savings in healthcare resources that can occur if low-burden countries invest in HIV/AIDS prevention now [39-42]. This may require different political and technical strategies moving forward. We worked collaboratively with UNAIDS to generate our HIV/AIDS mortality and prevalence estimates for GBD 2010; however, there are three main methodological differences that are important to note because they result in variations between GBD 2010 and UNAIDS’ published 2012 country year specific estimations [43-47]. First, on the basis of our discussions with UNAIDS [48], for a number of countries with high-quality vital registration data, we have based our assessments on those sources rather than epidemic models. Many of these countries are high-income, but they also include Uruguay and a number of Caribbean countries (Table 1). Second, for Thailand and Panama, we used UNAIDS 2010 assessments rather than their 2012 revision assessments because of the large divergence between national sources such as vital registration and the 2012 assessment. Since GBD 2010 was published around the same time as the UNAIDS 2012 report, the UNAIDS 2012 revision estimates used in GBD 2010 were preliminary [16]. As a result of the UNAIDS and GBD 2010 collaboration, several of the preliminary UNAIDS 2012 mortality estimates were adjusted; given the frequency of updates and methodological advances, tracing the evolution of specific country estimates across different sources was challenging. Thailand and Panama are examples of countries that were significantly adjusted after our exchange; however, these adjustments did not occur in time for inclusion in GBD 2010 [5,47]. Other countries that were significantly adjusted after our exchange and could not be included in GBD 2010 include Brazil, Central African Republic, Ethiopia and Haiti [5]; we are currently working with the UNAIDS Reference Group on Estimates and Projections to resolve these differences. The most significant difference in the GBD 2010 and UNAIDS 2012 mortality methodologies, however, was that we made our final HIV/AIDS mortality estimates fit within all-cause mortality estimates on the basis of independent demographic sources. This is fundamentally different from the UNAIDS single-cause modelling approach, which assumes that the data sources used for modelling HIV/AIDS mortality are sufficiently robust to obviate the need for any postestimation review. The empirical basis for assessing the HIV/AIDS epidemic in many countries, however, is rather weak; the number of antenatal care clinics that report data is small and the age–sex specific progression assumptions used in Spectrum, the UNAIDS modelling platform, have a very large impact on the production of their HIV/AIDS mortality estimates [45-47]. On the contrary, demography and the measurement of mortality in populations have a substantially longer history than descriptive epidemiology, certainly for HIV/AIDS. As a result, there are often more datasets available to estimate all-cause mortality, especially for those countries most affected by the epidemic [49]. In most countries, uncertainty intervals for total mortality are considerably smaller than for any significant cause of death, giving us greater faith in these estimates over any cause-specific estimate and thus validating the necessity of the all-cause mortality adjustment [50]. As the all-cause mortality fit is based on uncertainty surrounding the cause-specific estimates [1], this analytical step had a greater impact on causes with large uncertainties surrounding their estimates. For example, the average percentage change over the years in the HIV/AIDS mortality estimates before and after the all-cause mortality adjustment for Nigeria and Cuba were −26.1 and −0.2%, respectively. Of the 187 countries for which HIV/AIDS mortality estimates were generated, 24 countries were adjusted by more than 20% on average across the years and two countries did not have overlapping confidence intervals with the original UNAIDS estimates after the all-cause mortality adjustment (Bahamas and Zimbabwe). If there is a bias at present in the analysis, our major concern is that, due to the underestimation of HIV/AIDS uncertainty by UNAIDS in some key countries, other GBD 2010 causes are inappropriately adjusted more. As a result of these three main methodological differences, UNAIDS does not necessarily support the HIV/AIDS mortality estimates published in the GBD 2010 study. It is important to note, however, that despite numeric differences between GBD 2010 and UNAIDS’ 2012 estimates, uncertainty intervals are overlapping at the global level and, more importantly, show similar trends in HIV/AIDS mortality over time [50]. There are some countries where the HIV/AIDS estimates are still particularly unreliable. For the most part, these are countries with mediocre vital registration systems and concentrated epidemics that are very sensitive to estimates of the population at risk (e.g. Russia and Colombia). Due to the nature of these epidemics, the number of HIV/AIDS deaths captured in the vital registration systems are low and, thus, the UNAIDS 2012 estimates for these countries are significantly above the country-recorded HIV/AIDS deaths. The use of UNAIDS HIV/AIDS estimates for these countries in GBD 2010 resulted in surprisingly large HIV/AIDS burdens when compared with other causes. For example, HIV/AIDS ranked as one of the top four leading causes of DALYs in 2010 for both Colombia and Russia (Fig. 3). Other countries with a similar HIV/AIDS estimation problem include Guyana, Suriname and Venezuela, as well as Estonia, Latvia and Lithuania. In these cases, further work is needed to understand the marked divergence between different modelling approaches. Given the importance of sustaining the efforts to counteract the HIV/AIDS epidemic, it will be important to continue tracking the magnitude of the HIV/AIDS epidemic and also its importance relative to other diseases and injuries. The GBD 2010 effort will be continued and can provide regular updates of the burden of disease at the national level. This will provide a mechanism to incorporate new data on HIV/AIDS as well as other diseases and injuries and levels of all-cause mortality as they become available. We believe that the best science and data should be brought to bear on the estimation of each disease, injury and risk in each country. Although the engagement of local scientists, whether in government or not, can improve science, this can also stagnate and bias modelling efforts due to the politics surrounding these estimates. Unlike the UNAIDS bi-annual effort, the GBD work does not require agreement with countries; the science of measurement and the politics of measurement are kept distinct. UNAIDS has spearheaded major advances in HIV/AIDS surveillance and modelling. In some cases, however, the political requirement to consult with ministries of health has meant that estimates are not published for particular countries. For example, in the UNAIDS 2012 report, no precise mortality estimates were published for China, India or Russia [5]. There are several areas for improvements in the estimation of HIV/AIDS that follow from the GBD analysis. First, for countries where the evidence on patterns of all-cause mortality are different than what is implied by UNAIDS, we believe that further work on the age pattern of HIV/AIDS deaths and the robustness of the demographic sources is a high priority. Second, there are opportunities to improve the estimation process in UNAIDS’ Spectrum/Estimation and Projection Package (EPP) model to capture heterogeneity in incidence by age and sex in the EPP phase, explore more fully the evidence on the age and sex patterns of death in the Spectrum component and address relatively implausibly narrow uncertainty intervals produced for countries with large epidemics [45-47]. Third, in countries with complete vital registration, such as many countries in Latin America and Eastern Europe, research on misclassification of HIV/AIDS deaths is urgently needed to improve the tracking of HIV/AIDS-related mortality. Fourth, research on why verbal autopsy has proven so poor at recording HIV-related deaths would be important, as verbal autopsy is likely to be more widely collected in many low-resource settings. Moving forward, efforts need be made to collect the best evidence on the evolution of HIV/AIDS and other leading health problems, for this evidence is an essential global public good that can foster a sustained coherent response to current and future global health challenges.

Acknowledgements

We thank the UNAIDS Reference Group on Estimates, Models and Projections for patiently working with us as we developed our HIV/AIDS models for GBD 2010. We also thank the Global Burden of Disease team for their expertise and support. This publication resulted from research supported by the Bill & Melinda Gates Foundation.

Conflicts of interest

There are no conflicts of interest.
  31 in total

1.  A strategic revolution in HIV and global health.

Authors: 
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

2.  GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology.

Authors:  Christopher J L Murray; Majid Ezzati; Abraham D Flaxman; Stephen Lim; Rafael Lozano; Catherine Michaud; Mohsen Naghavi; Joshua A Salomon; Kenji Shibuya; Theo Vos; Alan D Lopez
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

3.  Mortality from HIV in the Global Burden of Disease study - authors' reply.

Authors:  Rafael Lozano; Katrina F Ortblad; Alan D Lopez; Christopher J L Murray
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

Review 4.  Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.

Authors:  Andrew Creese; Katherine Floyd; Anita Alban; Lorna Guinness
Journal:  Lancet       Date:  2002-05-11       Impact factor: 79.321

5.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

Review 6.  Scale-up of HIV treatment through PEPFAR: a historic public health achievement.

Authors:  Wafaa M El-Sadr; Charles B Holmes; Peter Mugyenyi; Harsha Thirumurthy; Tedd Ellerbrock; Robert Ferris; Ian Sanne; Anita Asiimwe; Gottfried Hirnschall; Rejoice N Nkambule; Lara Stabinski; Megan Affrunti; Chloe Teasdale; Isaac Zulu; Alan Whiteside
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

7.  Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme.

Authors:  U D'Alessandro; B O Olaleye; W McGuire; P Langerock; S Bennett; M K Aikins; M C Thomson; M K Cham; B A Cham; B M Greenwood
Journal:  Lancet       Date:  1995-02-25       Impact factor: 79.321

8.  The Spectrum projection package: improvements in estimating incidence by age and sex, mother-to-child transmission, HIV progression in children and double orphans.

Authors:  J Stover; P Johnson; T Hallett; M Marston; R Becquet; I M Timaeus
Journal:  Sex Transm Infect       Date:  2010-12       Impact factor: 3.519

9.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

10.  Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study.

Authors:  Greg W Fegan; Abdisalan M Noor; Willis S Akhwale; Simon Cousens; Robert W Snow
Journal:  Lancet       Date:  2007-09-22       Impact factor: 79.321

View more
  73 in total

1.  Association between intoxication at last sexual intercourse and unprotected sex among men and women in Uganda.

Authors:  Bradley Townsend Kerridge; Delivette Castor; Phu Tran; Matthew Barnhart; Roger Pickering
Journal:  J Infect Dev Ctries       Date:  2014-11-13       Impact factor: 0.968

2.  Patient-Reported Adverse Effects Associated with Combination Antiretroviral Therapy and Coadministered Enzyme-Inducing Antiepileptic Drugs.

Authors:  Melissa A Elafros; Gretchen L Birbeck; Joseph C Gardiner; Omar K Siddiqi; Izukanji Sikazwe; Nigel Paneth; Christopher M Bositis; Jason F Okulicz
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 3.  Reliability and validity of depression assessment among persons with HIV in sub-Saharan Africa: systematic review and meta-analysis.

Authors:  Alexander C Tsai
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

4.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

5.  Morbidity benefit conferred by childhood immunisation in relation to maternal HIV status: a meta-analysis of demographic and health surveys.

Authors:  Olatunji O Adetokunboh; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2018-09-13       Impact factor: 3.452

6.  Correlates of viral suppression among HIV-infected men who have sex with men and transgender women in Lima, Peru.

Authors:  Katherine M Rich; Javier Valencia Huamaní; Sara N Kiani; Robinson Cabello; Paul Elish; Jorge Florez Arce; Lia N Pizzicato; Jaime Soria; Jeffrey A Wickersham; Jorge Sanchez; Frederick L Altice
Journal:  AIDS Care       Date:  2018-05-30

7.  Impact of a primary care national policy on HIV screening in France: a longitudinal analysis between 2006 and 2013.

Authors:  Jonathan Sicsic; Olivier Saint-Lary; Elisabeth Rouveix; Nathalie Pelletier-Fleury
Journal:  Br J Gen Pract       Date:  2016-09-26       Impact factor: 5.386

8.  Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans.

Authors:  Matthew J Feinstein; June-Ho Kim; Prossy Bibangambah; Ruth Sentongo; Jeffrey N Martin; Alexander C Tsai; David R Bangsberg; Linda Hemphill; Virginia A Triant; Yap Boum; Peter W Hunt; Samson Okello; Mark J Siedner
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-07       Impact factor: 2.205

9.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

10.  Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Authors:  Joseph R Francica; Daniel E Zak; Caitlyn Linde; Emilio Siena; Carrie Johnson; Michal Juraska; Nicole L Yates; Bronwyn Gunn; Ennio De Gregorio; Barbara J Flynn; Nicholas M Valiante; Padma Malyala; Susan W Barnett; Pampi Sarkar; Manmohan Singh; Siddhartha Jain; Margaret Ackerman; Munir Alam; Guido Ferrari; Andres Salazar; Georgia D Tomaras; Derek T O'Hagan; Alan Aderem; Galit Alter; Robert A Seder
Journal:  Blood Adv       Date:  2017-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.